Form 10-Q - Quarterly report [Sections 13 or 15(d)]

US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Biogen (NASDAQ:BIIB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Haga Click aquí para más Gráficas Biogen.

Biogen (NASDAQ:BIIB)
Gráfica de Acción Histórica
De May 2023 a May 2024

Haga Click aquí para más Gráficas Biogen.

Noticias sobre Biogen Inc BIIB

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Jueves 16 de Mayo 2024 (2 días hace) • GlobeNewswire Inc.

Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Jueves 16 de Mayo 2024 (2 días hace) • PR Newswire (US)

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
Martes 14 de Mayo 2024 (3 días hace) • GlobeNewswire Inc.

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Martes 14 de Mayo 2024 (3 días hace) • PR Newswire (US)

Biogen Reports Progress on Corporate Responsibility Priorities
Jueves 2 de Mayo 2024 (2 semanas hace) • GlobeNewswire Inc.

Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Domingo 31 de Marzo 2024 (2 meses hace) • PR Newswire (US)

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
Miércoles 6 de Marzo 2024 (2 meses hace) • GlobeNewswire Inc.

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
Lunes 4 de Marzo 2024 (2 meses hace) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Lunes 26 de Febrero 2024 (3 meses hace) • Edgar (US Regulatory)

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
Viernes 23 de Febrero 2024 (3 meses hace) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Jueves 22 de Febrero 2024 (3 meses hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Miércoles 21 de Febrero 2024 (3 meses hace) • Edgar (US Regulatory)

Más de Biogen Inc Artículos de Noticias

Perception Capital Corpo...

BNP Paribas Issuance

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones